{"id":"mass-treatment-with-oral-azithromycin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Vomiting"},{"rate":"rare","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin works by binding to bacterial ribosomes and preventing peptide bond formation, thereby stopping bacterial protein synthesis. In mass drug administration (MDA) programs, oral azithromycin is distributed to entire populations or communities to reduce the prevalence and transmission of targeted pathogens, particularly in trachoma elimination campaigns and other neglected tropical disease control efforts.","oneSentence":"Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and in mass treatment campaigns is used to reduce transmission of infectious diseases at the population level.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:02.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mass treatment for trachoma elimination"},{"name":"Population-level antimicrobial prophylaxis in neglected tropical disease control programs"}]},"trialDetails":[{"nctId":"NCT04185402","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-29","conditions":"Trachoma","enrollment":3931},{"nctId":"NCT06289647","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma B","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2024-10","conditions":"Trachoma","enrollment":""},{"nctId":"NCT04716712","phase":"PHASE4","title":"Infant Mortality Reduction by the Mass Administration of Azithromycin","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-04","conditions":"Child Mortality","enrollment":694400},{"nctId":"NCT03490123","phase":"PHASE4","title":"Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-04-16","conditions":"Yaws","enrollment":56000},{"nctId":"NCT01202331","phase":"PHASE4","title":"Tripartite International Research for the Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-11","conditions":"Trachoma, Chlamydia","enrollment":29000},{"nctId":"NCT01955252","phase":"PHASE3","title":"Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2013-03","conditions":"Yaws","enrollment":16000},{"nctId":"NCT00322972","phase":"PHASE4","title":"Trachoma Amelioration in Northern Amhara (TANA)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-06","conditions":"Trachoma, Chlamydia","enrollment":33000},{"nctId":"NCT00221364","phase":"PHASE4","title":"Trachoma Elimination Follow-up","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2003-03","conditions":"Trachoma, Chlamydia","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zithromax"],"phase":"marketed","status":"active","brandName":"mass treatment with oral azithromycin","genericName":"mass treatment with oral azithromycin","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and in mass treatment campaigns is used to reduce transmission of infectious diseases at the population level. Used for Mass treatment for trachoma elimination, Population-level antimicrobial prophylaxis in neglected tropical disease control programs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}